Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Public Sector Pension Investment Board

Public Sector Pension Investment Board reduced its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 192,739 shares of the company’s stock after selling 6,400 shares during the quarter. Public Sector Pension Investment Board owned about 0.21% of Myriad Genetics worth $5,279,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in shares of Myriad Genetics by 13.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 53,568 shares of the company’s stock valued at $1,143,000 after buying an additional 6,337 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Myriad Genetics by 3.0% during the 1st quarter. California State Teachers Retirement System now owns 88,787 shares of the company’s stock worth $1,893,000 after purchasing an additional 2,564 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Myriad Genetics during the 1st quarter worth approximately $606,000. DekaBank Deutsche Girozentrale grew its position in shares of Myriad Genetics by 9.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 35,272 shares of the company’s stock valued at $751,000 after purchasing an additional 2,980 shares in the last quarter. Finally, Clarus Wealth Advisors purchased a new stake in Myriad Genetics in the 2nd quarter valued at $247,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Insider Activity

In related news, Director Heinrich Dreismann sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $27.05, for a total transaction of $270,500.00. Following the transaction, the director now owns 121,648 shares of the company’s stock, valued at $3,290,578.40. This trade represents a 7.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Paul J. Diaz sold 15,000 shares of the business’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the transaction, the chief executive officer now owns 962,378 shares in the company, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,012 shares of company stock valued at $1,900,485 in the last ninety days. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MYGN. Scotiabank boosted their price target on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upped their price objective on Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a report on Wednesday, August 7th. Piper Sandler cut their target price on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research note on Monday, November 11th. TD Cowen raised their price objective on Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley reduced their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.36.

Myriad Genetics Price Performance

Shares of NASDAQ MYGN opened at $16.27 on Monday. The stock has a market cap of $1.48 billion, a P/E ratio of -12.52 and a beta of 1.93. Myriad Genetics, Inc. has a twelve month low of $14.72 and a twelve month high of $29.30. The stock has a 50 day moving average of $21.06 and a two-hundred day moving average of $24.17. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.